Can-Fite BioPharma (CANF) Competitors $0.69 -0.01 (-1.14%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$0.69 0.00 (-0.01%) As of 08/8/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. ACXP, DWTX, XFOR, APRE, SNGX, SONN, CHRO, ADXN, CLRB, and CYCNShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Acurx Pharmaceuticals (ACXP), Dogwood Therapeutics (DWTX), X4 Pharmaceuticals (XFOR), Aprea Therapeutics (APRE), Soligenix (SNGX), Sonnet BioTherapeutics (SONN), Chromocell Therapeutics (CHRO), Addex Therapeutics (ADXN), Cellectar Biosciences (CLRB), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors Acurx Pharmaceuticals Dogwood Therapeutics X4 Pharmaceuticals Aprea Therapeutics Soligenix Sonnet BioTherapeutics Chromocell Therapeutics Addex Therapeutics Cellectar Biosciences Cyclerion Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Do analysts recommend ACXP or CANF? Acurx Pharmaceuticals currently has a consensus target price of $160.00, suggesting a potential upside of 3,479.42%. Can-Fite BioPharma has a consensus target price of $14.00, suggesting a potential upside of 1,937.55%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Can-Fite BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of ACXP or CANF? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer ACXP or CANF? In the previous week, Acurx Pharmaceuticals had 4 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 4 mentions for Acurx Pharmaceuticals and 0 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 beat Acurx Pharmaceuticals' score of -0.34 indicating that Can-Fite BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Acurx Pharmaceuticals Neutral Can-Fite BioPharma Neutral Is ACXP or CANF more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -526.78% -223.78% Can-Fite BioPharma N/A N/A N/A Which has more volatility and risk, ACXP or CANF? Acurx Pharmaceuticals has a beta of -1.27, suggesting that its stock price is 227% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Which has stronger earnings & valuation, ACXP or CANF? Can-Fite BioPharma has higher revenue and earnings than Acurx Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$14.00-0.32Can-Fite BioPharma$674K3.61-$7.63M-$1.79-0.38 SummaryCan-Fite BioPharma beats Acurx Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.43M$857.25M$5.51B$20.74BDividend YieldN/A4.84%4.60%3.66%P/E Ratio-0.381.1430.0128.05Price / Sales3.6126.66450.7256.18Price / CashN/A19.5636.7723.05Price / Book0.396.548.184.33Net Income-$7.63M-$4.07M$3.26B$994.32M7 Day Performance4.66%121.77%6.13%1.97%1 Month Performance-33.61%1.87%0.07%-1.60%1 Year Performance-73.77%22.82%36.31%14.39% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.6066 of 5 stars$0.69-1.1%$14.00+1,937.5%-73.8%$2.43M$674K-0.388ACXPAcurx Pharmaceuticals2.1547 of 5 stars$0.29-4.8%$8.00+2,636.0%-88.1%$9.44MN/A-0.423News CoverageUpcoming EarningsAnalyst UpgradeDWTXDogwood Therapeutics1.2645 of 5 stars$4.86+0.2%$10.00+105.8%N/A$9.27MN/A-0.275News CoverageXFORX4 Pharmaceuticals4.5582 of 5 stars$1.58-1.3%$72.33+4,478.1%-92.1%$9.26M$2.56M0.7480Earnings ReportAPREAprea Therapeutics2.8371 of 5 stars$1.70+2.4%$15.50+811.8%-49.4%$9.18M$1.50M-0.727News CoverageUpcoming EarningsSNGXSoligenix2.2638 of 5 stars$3.11+13.5%$6.00+92.9%-7.6%$8.94M$120K-0.7220News CoverageGap UpHigh Trading VolumeSONNSonnet BioTherapeutics2.4996 of 5 stars$2.81flat$20.00+611.7%-45.6%$8.90M$20K0.0010Upcoming EarningsGap UpCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-80.9%$8.69MN/A-1.084Gap UpHigh Trading VolumeADXNAddex Therapeutics2.8818 of 5 stars$8.24+1.7%$30.00+264.3%-0.3%$8.58M$460K-24.2230CLRBCellectar Biosciences2.7895 of 5 stars$5.06+7.2%$375.00+7,311.1%-91.8%$8.54MN/A-0.2310News CoverageUpcoming EarningsCYCNCyclerion Therapeutics2.4464 of 5 stars$2.79+7.5%N/A-18.8%$8.33M$2M-2.4030Earnings Report Related Companies and Tools Related Companies Acurx Pharmaceuticals Alternatives Dogwood Therapeutics Alternatives X4 Pharmaceuticals Alternatives Aprea Therapeutics Alternatives Soligenix Alternatives Sonnet BioTherapeutics Alternatives Chromocell Therapeutics Alternatives Addex Therapeutics Alternatives Cellectar Biosciences Alternatives Cyclerion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts